
Best Stocks: A name that's a standout in its sector, with terrific fundamentals and nice chart set-up

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
18 minutes ago
- Yahoo
Is This the Right Time to Consider Healthcare ETFs?
U.S. healthcare stocks are currently trading at the biggest discount relative to the broader market in 30 years, according to Barrons, presenting a solid opportunity for investors looking for stability and potential growth. The Health Care Select Sector SPDR XLV, which mirrors the sector's performance, has fallen 9.6% over the past year while the broad SPDR S&P 500 ETF Trust SPY climbed about 16%. This has pushed healthcare stocks to trade at a historic valuation discount compared to the broader market. The sector has been struggling due to concerns over political and regulatory uncertainties, including government policies targeting prescription drug prices, tariffs on pharmaceuticals, and reduced funding in health research and Medicaid. The expiry of drug patents and setbacks faced by major companies have contributed to the sector's another sign of waning investor interest, healthcare ETFs have recorded 12 straight months of net outflows through July, totaling $11.5 billion. This represents the largest outflow of any sector, according to State Street Investment Management. Is the Sector Ready for a Rebound? The healthcare sector has gathered momentum with XLV gaining 4.2% over the past week versus a decline of 0.5% for SPY. This signals potential turnaround and came on the back of attractive valuation and growing hedge fund's exposure. Attractive Valuation The sector is currently trading at a forward P/E ratio of around 16, substantially lower than the S&P 500's P/E ratio of about 22 and far below technology's P/E ratio of 30. This discount is the widest seen in three decades, making healthcare stocks some of the most undervalued in the market relative to their earnings potential. Buffett Entry Provides A Major Boost Warren Buffett's Berkshire Hathaway investment in UnitedHealth UNH lifted sentiment, bolstering confidence in managed-care names. In the latest 13F filing, Berkshire Hathaway disclosed that it bought more than 5 million shares in UNH in the second quarter, valued at approximately $1.6 billion. The stock has soared more than 10% in a week (read: Insights Into 13F Filings: ETFs to Invest in Like Billionaires). Other Hedge Funds Increase Exposure Per the latest 13F filings, most hedge funds ramped up exposure to healthcare stocks. Stanley Druckenmiller, renowned investor and head of Duquesne Family Office, has increased his exposure to healthcare stocks as part of a strategic portfolio adjustment during the second quarter. His portfolio, valued at around $3.06 billion, shows a prominent tilt toward innovative healthcare and pharmaceuticals, reflecting his confidence in the sector's growth managers also highlighted exposure to Regeneron REGN and other life sciences names via both equity and calls, showing targeted science-driven bets. Corporate Action Stocks like CVS Health CVS gained on analyst upgrades. Novo Nordisk NVO surged following the FDA approval for a new use of its weight-loss drug (read: NVO Wins FDA Approval for MASH Treatment: ETFs Likely to Gain). Rotation to Defensive Sectors Amid growing skepticism over lofty tech valuations, investors are shifting toward more stable, defensive sectors. This has helped healthcare stocks attract renewed attention as a safer haven. Healthcare generally outperforms during periods of low growth and high uncertainty, as evidenced in the current macro environment. AI and Technology Integration in Healthcare The emergence of AI-driven healthcare initiatives, such as the Stargate project, promised to revolutionize cancer research and healthcare technologies. This created optimism about innovation-led growth in the sector, attracting investments focused on AI and biotech companies advancing healthcare solutions. Solid Zacks Sector Rank The potential upside to the healthcare sector is confirmed by the Zacks Sector Rank in the top 44%, with about 75% of the industries ranking in the top 41%. This suggests that the momentum built up in the healthcare space lately will likely continue in the coming weeks. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Regeneron Pharmaceuticals, Inc. (REGN) : Free Stock Analysis Report UnitedHealth Group Incorporated (UNH) : Free Stock Analysis Report Novo Nordisk A/S (NVO) : Free Stock Analysis Report CVS Health Corporation (CVS) : Free Stock Analysis Report SPDR S&P 500 ETF (SPY): ETF Research Reports Health Care Select Sector SPDR ETF (XLV): ETF Research Reports This article originally published on Zacks Investment Research ( Zacks Investment Research Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
18 minutes ago
- Yahoo
Nvidia's Earnings Could Make Or Break Momentum ETFs
A sudden tumble in the high-flying factor names could be paving the way for a reversal, say Goldman Sachs traders, putting the spotlight on ETFs tied to the factor ahead of NVIDIA Corp.'s (NASDAQ:NVDA) closely followed earnings next week. Nvidia's quarterly results could decide the fate of momentum stocks and the ETFs that track them, after a two-week slide put the high-flying trade under pressure. Nvidia is down more than 4% in the past week. Track its prices live, here. Goldman's High Beta Momentum basket, which bundles together the latest winners in the market and shorts losers, fell 13% from Aug 6 to Aug 19, its fourth drop of over 10% this year, as reported by Bloomberg. Historically, these sharp declines have tended to reverse rapidly from such a point. Goldman Sachs pointed out that in previous instances when the basket declined 10% or more in five days, it recovered during the next week, 80% of the time, with median returns of 4.5% during the next week and over 11% over the subsequent month. The ETF Angle Momentum-based ETFs such as the iShares MSCI USA Momentum Factor ETF (BATS:MTUM) and Invesco Dorsey Wright Momentum ETF (NASDAQ:PDP) offer investors direct exposure to the same high-octane growth stocks that dominate Goldman's basket, the likes of Nvidia, Advanced Micro Devices Inc (NASDAQ:AMD), and Palantir Technologies Inc (NASDAQ:PLTR). That makes the funds especially sensitive to whether Nvidia's earnings next week can revive enthusiasm in AI-related equities or deepen the selloff. ETFs that follow the momentum factor have also experienced uneven returns in 2025, with several abrupt swings related to the AI trade. The latest rout also questions whether these vehicles can be used as tactical trades or not long-term positions. What's Driving The Sell-off Losses in AI leaders such as Palantir, AMD, Super Micro Computer Inc (NASDAQ:SMCI), and even Nvidia, pulled the basket down. These formerly crowded trades now face profit-taking, high valuations, and nervousness about China's competitive squeeze. The Risk To Rebounds Although Goldman's traders point out that momentum has previously rebounded following steep drops, some warn that the factor has been erratic throughout the year. Bloomberg Intelligence's Christopher Cain said that high-momentum stocks have some of the most costly valuations relative to low momentum in history. The last catalyst will depend on Nvidia's earnings next week. As the heaviest weight in the S&P 500 and Nasdaq 100, the chipmaker's report could make or break whether momentum ETFs produce another record rebound — or this is merely the beginning of a more significant correction. Read Next: Photo: Chung-Hao-Lee via Shutterstock UNLOCKED: 5 NEW TRADES EVERY WEEK. Click now to get top trade ideas daily, plus unlimited access to cutting-edge tools and strategies to gain an edge in the markets. Get the latest stock analysis from Benzinga? NVIDIA (NVDA): Free Stock Analysis Report This article Nvidia's Earnings Could Make Or Break Momentum ETFs originally appeared on © 2025 Benzinga does not provide investment advice. All rights reserved. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
33 minutes ago
- Yahoo
Are Wall Street Analysts Bullish on Federal Realty Stock?
Federal Realty Investment Trust (FRT), with a market cap of $8.3 billion, is a real estate company that owns, operates and redevelops high-quality retail-based properties located primarily in major coastal markets. The North Bethesda, Maryland-based company's retail properties are anchored by supermarkets, drugstores, or high-volume, value-oriented retailers, which provide essential 1consumer necessities. Shares of this retail REIT have underperformed the broader market over the past 52 weeks. FRT has declined 14.4% over this time frame, while the broader S&P 500 Index ($SPX) has gained 14.3%. Moreover, on a YTD basis, the stock is down 13.6%, compared to SPX's 9% rise. More News from Barchart As SoFi Launches International Money Transfer Services, How Should You Play SOFI Stock? This Cannabis Stock Just Transformed Into a Bitcoin Treasury Play. Should You Buy Shares Now? Profiting from Volatility: CRWV Long Straddle Trade Setup Get exclusive insights with the FREE Barchart Brief newsletter. Subscribe now for quick, incisive midday market analysis you won't find anywhere else. Narrowing the focus, FRT has also lagged behind the Real Estate Select Sector SPDR Fund's (XLRE) 1% uptick over the past 52 weeks and 2.5% return on a YTD basis. On Aug. 6, Federal Realty reported Q2 results that topped Wall Street expectations. Its funds from operations stood at $165.5 million, or $1.91 per share, beating the consensus estimate of $1.73 per share. Net income was $153.9 million, or $1.78 per share, while revenue came in at $311.5 million, slightly above forecasts of $310.7 million. The company projects full-year funds from operations in the range of $7.16 to $7.26 per share. Shares of the company declined marginally post the announcement. For the current fiscal year, ending in December, analysts expect FRT's FFO to grow 5.9% year over year to $7.17 per share. The company's FFO surprise history is mixed. It exceeded or met the consensus estimates in three of the last four quarters, while missing on another occasion. Among the 18 analysts covering the stock, the consensus rating is a 'Moderate Buy' which is based on nine 'Strong Buy,' one 'Moderate Buy,' and eight 'Hold' ratings. This configuration has been consistent for the past months. On Aug. 8, Evercore ISI analyst Steve Sakwa reaffirmed an 'Outperform' rating on Federal Realty Investment while slightly lowering the price target from $109 to $107, a 1.8% reduction. The mean price target of $107.50 represents an 11.2% premium from FRT's current price levels, while the Street-high price target of $115 suggests an upside potential of 18.9%. On the date of publication, Kritika Sarmah did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data